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Prostate cancerycomb group protein Bmi1 promotes prostate tumorigenesis. Bmi1 is detected at
higher levels in androgen-independent PC3 and DU145 than in androgen-dependent LNCaP prostate cancer
(CaP) cells. Ectopic Bmi1 enhanced the expression of human telomerase reverse transcriptase (hTERT) and
suppressed the exression of p16INK4A and p14ARF in CaP cells. Consistent with these observations,
immunohistochemical staining of 51 cases of primary CaP specimens revealed 1.4 fold (p=0.014) and 1.3
fold (p=0.051) higher levels of Bmi1-positive cells in carcinoma compared to normal prostatic epithelial cells
and PIN, respectively. In primary CaPs, Bmi1 expression was associated with a reduction in p16INK4A and
p14ARF. Furthermore, in comparison to empty vector-transfected cells, Bmi1-expressing DU145 cells formed
signiﬁcantly larger tumors in NOD/SCID mice. Taken together, we demonstrate that Bmi1 promotes prostate
tumorigenesis.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe polycomb group (PcG) Bmi1 gene maintains the proliferative
potential and self-renewal activity of hematopoietic and neural stem
cells [1,2]. This is in part attributable to Bmi1-mediated suppression of
the transcription of p16INK4A, p19ARF/p14ARF, and E4F1 [3–5]. This
developmental function of Bmi1 is in line with its oncogenic role in
leukemia. The Bmi1 gene was initially isolated as an oncogene which
cooperates with c-Myc in retrovirus-induced B and T cell leukemia
[6,7]. Overexpression of Bmi1 transforms lymphocytes [8,9] and was
detected in 25% of mantle cell lymphoma [10]. Bmi1 positivity is
associated with unfavorable prognosis in patients with diffuse large B
cell lymphomas and myelodysplastic syndrome [11,12]. Recently,
increases in Bmi1 have also been reported in non-hematopoietic
malignancies including non-small cell lung cancer (NSCLC) [13], colon
cancer [14], medulloblastomas [15], breast cancer [16], and nasophar-
yngeal carcinoma [17].
Consistent with its role in inhibiting p16INK4A and p19ARF
transcription, Bmi1 induces the bypassing of senescence. Bmi1−/−
hematopoietic progenitors express increased p16INK4A and p19ARF, and
accumulate high levels of the senescence marker SA-β-Gal [5],
consistent with the observed diminishing of self-renewal potential
of Bmi1−/− hematopoietic stem cells [1]. Bmi1−/− mouse embryonicd at Tel.: +1 905 522 1155, ext.
Hospital, 50 Charlton Ave East,
t. 35168; fax: +1 905 521 6181.
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ll rights reserved.ﬁbroblasts (MEFs) undergo premature senescence [18] and over-
expression of Bmi1 in MEFs and human ﬁbroblasts extends their
replicative life spans [18,19]. Additionally, it has been shown that Bmi1
immortalizes human nasopharyngeal and mammary epithelial cells
by enhancing human telomerase reverse transcriptase (hTERT)
activity [17,20].
A potential oncogenic role of Bmi1 has also been suggested in
prostate cancer. Increases in Bmi1 mRNA were detected in prostate
cancer cell lines, xenografts derived from prostate cancer cells and
human primary prostate carcinoma, as well as mouse primary
prostate tumors derived from the TRAMP transgenic mouse model
[21]. Prostate cancer patients with an 11-gene signature, which is
associated with Bmi1 expression, are likely to have unfavorable
prognosis than those without this signature [21]. Additionally,
metastatic prostate carcinoma precursor cells that are double-positive
for Bmi1 and the polycomb-group protein EZH2 aremore tumorigenic
than those which are negative for both proteins [22]. However, the
expression status of the Bmi1 protein in primary prostate cancer and
the exact role of Bmi1 in prostate tumorigenesis have not been
thoroughly investigated.
In this investigation, we have examined the Bmi1 protein in
prostate cancer cell lines and in 51 cases of primary prostate cancer by
immunohistochemistry. In comparison to normal prostatic epithelial
cells, Bmi1 protein was expressed at higher levels in PINs and
carcinomas. Additionally, a high level of Bmi1 is associated with
reduction in p16INK4A and p14ARF in prostate carcinoma. This is in line
with our in vitro study showing that ectopic Bmi1 reduces p16INK4A
and p14ARF expression in DU145 prostate cancer cells and enhances
Table 1
Prostate cancer specimens used in this investigation
Patient Age Gleason Capsule
involvement
pT Perineural
invasion
pN PSA (ng/mL)
1 62 3+3 No pT2c Unknown pNX 7.66
2 68 3+3 Yes pT2c Yes pN0 Unknown
3 61 3+4 No pT2c Unknown pN0 5.67
4 57 3+4 Yes pT2c Unknown pN0 4.6
5 58 3+3 No pT2c Unknown pN0 7.2
6 67 3+5 No pT2c Yes pN0 5.8
7 57 3+3 Yes pT3b Yes pNX 7.49
8 70 4+4 No pT2c Unknown pN0 21
9 61 3+4 Yes pT3a Unknown pNX 4.98
10 56 3+3 No pT2c Unknown pNX Unknown
11 60 4+3 Yes pT3a Unknown pN0 7.8
12 50 4+3 No pT2c Unknown pN0 13
13 69 3+4 Yes pT3b Yes pNX 3.7
14 67 3+4 No pT2c Unknown pNX 5.01
15 58 3+3 No pT2c Unknown pNX 13.58
16 61 4+3 Yes pT3a Yes pN0 24.07
17 52 3+3 Yes pT3b Unknown pN0 Unknown
18 68 3+4 Yes pT3a Yes pN0 4.4
19 65 3+3 No pT2c No pNX 4.4
20 66 3+4 No pT2c Unknown pN0 6.7
21 74 3+4 No pT2c Yes pNX Unknown
22 62 3+4 No pT2c Unknown pN0 5.16
23 62 3+4 No pT2c Yes pN0 4.48
24 63 3+4 Yes pT3a Yes pN0 8.7
25 67 3+3 No pT2a Unknown pNX 8.3
26 67 3+5 No pT2c Yes pN0 5.2
27 60 3+4 Yes pT2c Unknown pNX 5.1
28 59 3+3 Yes pT2c Yes pNX 5.69
29 65 3+3 No pT2c Yes pNX 5.48
30 50 3+4 No pT2c Yes pN0 6.4
31 64 3+4 Yes pT3a Yes pN0 9.69
32 51 3+4 No pT2a Unknown pNX 5.6
33 57 3+4 No pT2c Unknown pN0 20
34 67 3+3 No pT2c Yes pN0 5.01
35 53 3+4 Yes pT3a Unknown pNX 8.68
36 56 3+4 No pT2c Unknown pNX Unknown
37 65 3+4 Yes pT2c Yes pNX 5.07
38 69 3+5 Yes pT3a Yes pN0 6.7
39 60 3+4 No pT2c Yes pN0 9.86
40 58 3+4 No pT2c Unknown pNX 4.2
41 68 4+3 Yes pT3a Yes pN0 20
42 61 3+4 No pT2c No pNX 7.6
43 54 4+3 Yes pT3b Yes pN0 12
44 56 3+4 Yes pT2c Unknown pN0 9.7
45 65 4+4 No pT2a Yes pNX 8
46 55 3+3 Yes pT2a Unknown pNX 6.17
47 58 3+3 No pT2c Unknown pNX 5.32
48 73 4+3 No pT2c Unknown pNX 5.2
49 64 3+3 No pT2a Unknown pN0 7.9
50 67 3+3 No pT2c Unknown pNX 5.89
51 60 3+3 No pT2c Unknown pN0 6.7
643C. Fan et al. / Biochimica et Biophysica Acta 1782 (2008) 642–648DU145 cells to form xenograft tumors in immunocompromised mice.
Taken together, our observations reveal that Bmi1 promotes prostate
tumorigenesis, at least in part, by down-regulation of p16INK4A and
p16ARF.
2. Materials and methods
2.1. Cell lines and plasmids
LNCaP, PC3, DU145, MCF7, HeLa, and 293T cells were purchased
from ATCC, and cultured in RPMI-1640 (LNCaP), F12 (PC3), MEM
(DU145), and DMEM (MCF7, HeLa, and 293T) plus 10% FBS and 1%
Penicillin–Streptomycin (Invitrogen).
Human Bmi1 cDNA was ampliﬁed by RT-PCR from HeLa cells,
which was subsequently subcloned in pcDNA3 and pBabe retrovirus
vectors. pGL3-hTERTmin-Luc reporter plasmid, containing a 59 bp
region of the hTERT promoter (−208 to −150) which has been shown
to display maximal promoter activity [23], was constructed from HeLa
cell genomic DNA using routine molecular biology techniques.
2.2. Retroviral infection
Retroviral infection was performed following our published
procedure [24,25]. Brieﬂy, a gag-pol expressing vector and an
envelope-expressing vector (VSV-G) (Stratagene) were transiently
co-transfected with a designed retroviral plasmid into 293Tcells. After
48 h, the virus-containing medium was harvested, ﬁltered through a
0.45 μM ﬁlter, and centrifuged at 50,000 g for 90 min to concentrate
the retrovirus. Following the addition of 10 μg/ml of polybrene
(Sigma), the medium was used to infect cells. Infection for pBabe-
based constructs was selected in puromycin, while infection for
pLHCX-based constructs was selected in hygromycin.
2.3. Collecting primary prostate cancer
Prostate tissue was collected from patients who underwent radical
prostactomy at St. Joseph's Hospital in Hamilton, Ontario, Canada
under the approval from the local Ethics Board and consent from
patients. The patient cohort (51 CaP patients) used in this investiga-
tion represents the typical patient population treated in this center.
Cancers were examined and graded by pathologists of the Hospital.
51 primary prostate cancer specimens were collected. All patients in
our cohort have not received hormonal and radiation therapies prior
to surgery. Information regarding these specimens is presented in
Table 1.
2.4. Western blot
Cell lysates were prepared and western blot was performed
according to our published procedure [24]. 50 μg protein of total
lysate was separated on SDS-PAGE gel and transferred onto Immobi-
lon-P membranes (Millipore). Membranes were blocked with 5% skim
milk and then incubated with the indicated antibodies at room
temperature for 1 h. Signals were detected using an ECL Western
Blotting Kit (Amersham). Primary antibodies used were: polyclonal
anti-Bmi1 (1:100, Santa Cruz Biotechnology), polyclonal anti-p16INK4A
(1:500, Santa Cruz Biotechnology), and polyclonal anti-p14ARF
(1:5000, Sigma).
2.5. Immunoﬂuorescence and immunohistochemistry of Bmi1, p16INK4A,
and p14ARF as well as statistical analysis
Immunoﬂuorescence staining was carried out using the following
antibodies: a monoclonal anti-FLAG (M2, 1:500; Sigma), anti-Bmi1, and
FITC-Donkey anti-mouse IgG (1:200; Jackson Immuno Research).
Images were captured using Axiovert 200 M and AxioVision 3 software.Immunohistochemistry (IHC) was performed on 51 parafﬁn-
embedded, serially-cut prostate cancer tissues. IHC procedure was
optimized and did not produce detectable artiﬁcial staining that might
be associated with antigen-retrieval and ﬁxation, as control IgG
(negative control) did not generate detectable staining (Fig. 2). Brieﬂy,
slides were deparafﬁnized in xylene, cleared in ethanol series, and
heat-treated for 30 min in sodium citrate buffer (pH=6.0) in a food
steamer. Primary antibodies speciﬁc for Bmi1 (1:100, Santa Cruz
Biotechnology), p16INK4A (1:100, Santa Cruz Biotechnology), and
p14ARF (1:1000, Sigma) were incubated with the sections overnight
at 4 °C. Negative controls were incubated with a non-speciﬁc anti-
rabbit IgG. Biotinylated goat anti-rabbit IgG and Vector ABC reagent
(Vector Laboratories) were subsequently added according to the
manufacturer's instructions. Washes were performed with Tris-
buffered saline containing 0.1% Tween-20 (TBST). Chromogen reaction
was carried out with diaminobenzidine, and counterstaining was
donewith hematoxylin. Hematoxylin and eosin (H and E) stainingwas
carried out using a standard protocol.
Fig. 1. Expression of Bmi1 in prostate cancer cells. (A) LNCaP, PC3, DU145, and MCF7
(breast cancer cells) cells were examined for Bmi1 expression by western blot. (B) IF
staining of LNCaP, PC3, DU145, and MCF7 cells for Bmi1 protein. Nuclei were counter-
stained with DAPI (blue). Scale bar represents 10 μM.
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Eclipse 4.0 software (manual cell counter) for Windows. Approxi-
mately 1000 cells from randomly selected ﬁelds were counted for each
normal, PIN, and cancer foci per patient. Mean percentages of
positively-stained cells were then analyzed using GraphPad 4.0 for
Windows.
2.6. Generation of xenograft tumors in NOD/SCID mice
DU145 cells were enzymatically dissociated, resuspended in
serum-containing MEM/Matrigel mixture (1:1 volume), and kept at
4 °C until injection. An amount equal to 0.1 ml, containing 2×105 cells,
was subcutaneously injected into each ﬂank of 8-week-old male NOD
SCID mice (The Jackson Laboratory, Bar Harbor, Maine) using a 25-
gauge needle, for a total of 4 mice for each cell line. Mice were
inspected for tumor appearance, by observation and palpation, and
tumor growth was measured weekly using a caliper. Tumor volume
was determined using the standard formula: L×W2×0.52, where L
and W are the longest and shortest diameters, respectively. The
presence of each tumor nodule was conﬁrmed by necropsy. All animal
work was carried out according to experimental protocols approved
by the McMaster University Animal Research Ethics Board.
3. Results
3.1. Increases in Bmi1 protein in prostate cancer
To investigate an oncogenic role of Bmi1 in prostate cancer, we ﬁrst
examined the Bmi1 protein in the three most widely used CaP cell
lines, androgen-dependent LNCaP and androgen-independent PC3
and DU145 cells. While the presence of Bmi1 in PC3 and DU145 cells
was readily detected, we could not detect the Bmi1 protein in LNCaP
cells (Fig. 1A) even after prolonged exposure and using double the
amount of total cell lysate (100 μg) (50 μg cell lysates were used for
other lines, Fig. 1A). Although approximately two-fold less Bmi1
mRNAwas reported in LNCaP than in PC3 cells [21], our results suggest
that LNCaP cells express a substantially low (or undetectable) level of
Bmi1 protein. Immunoﬂuorescence (IF) detected Bmi1 protein in the
nucleus of PC3, DU145, andMCF7 cells, but not in the nucleus of LNCaP
cells (Fig. 1B).
We have further examined Bmi1 expression in primary CaPs.
Immunohistochemistry (IHC) staining of 51 primary CaP specimens
detected Bmi1 in normal prostate glands, PIN (data not shown), and
carcinoma (Fig. 2). To quantify the percentage of cells expressing Bmi1,
we have counted 1000 cells in individual tissues (normal prostate
glands, PINs, and carcinomas) for each of the 51 primary CaP
specimens. For each specimen, an average of 27.8% of epithelial cells
in normal prostatic glands and 30.9% in PIN tissues expressed Bmi1,
while a signiﬁcant 11.3% increase in Bmi1-positive cells was observed
in carcinoma (Table 2). This pattern of Bmi1 expression is in line with
the pattern of CBX7 expression, a PcGmember, in prostate cancer [26].
Taken together, we demonstrate increased levels of Bmi1 protein in
CaP, which is consistent with the reported increases in Bmi1mRNA in
prostate cancer [21].
3.2. Bmi1 suppresses p16INK4A and p14ARF expression as well as enhances
hTERT expression in prostate cancer
Bmi1 has been shown to inhibit the transcription of p16INK4A and
p14ARF [3,4]. To examine whether this is also the case in prostate
cancer, we have stably-expressed Bmi1 in DU145, PC3, and LNCaP
cells. Ectopic Bmi1 led to a modest decrease in endogenous p16INK4A,
which may be attributable to the DU145 cell expressing mutant
p16INK4A [27], and a clear reduction in endogenous p14ARF in DU145
and PC3, but not LNCaP (Fig. 3A, top panels). Ectopic Bmi1 was
expressed slightly higher than endogenous Bmi1 in DU145 and PC3cells, evidenced by a slight one-fold increase in Bmi1 protein detected
in Bmi1-transfected cells than in empty vector (pBabe) transfected
cells (Fig. 3A, bottom panels). Thus, the reduction of p16INK4A and
p14ARF in PC3 and DU145 cells by ectopic Bmi1 was not due to very
high levels of ectopic Bmi1. The fact that we did not observe decreases
in p16INK4A and p14ARF in LNCaP cells may be attributable to these cells
expressing very low levels of endogenous Bmi1, p16INK4A and p14ARF
proteins (Fig. 3A).
Bmi1 has been reported to induce hTERT expression in mammary
epithelial cells [20]. To address whether Bmi1 modulates hTERT
expression, we co-transfected a hTERT promoter reporter construct
(pGL3-hTERTmin-Luc) [23] together with Bmi1. In comparison to the
empty vector control, Bmi1 up-regulates hTERT expression (Fig. 3B).
3.3. Bmi1 positivity is associated with reduction in p16INK4A and p14ARF
in primary prostate cancer
To determine whether Bmi1 is associated with the reduction of
p16INK4A and p14ARF in primary CaP, we have examined the expression
of Bmi1, p16INK4A, and p14ARF proteins in 51 primary prostate cancer
tissues. All three proteins largely express in both basal and luminal
epithelial cells of prostate glands, with occasional staining detected in
Fig. 2. Expression of Bmi1 protein in primary prostate cancer tissues associates with reduction in p16INK4A and p14ARF. H and E (HE) and immunohistochemical (IHC) staining of
normal prostatic gland (Normal), PIN, and carcinomawith Bmi1-, p16INK4A- and p14ARF speciﬁc antibodies or control IgG (IgG). All tissues were from the same patient/slide. Scale bar
represents 40 μM. The inset areas are enlarged.
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of Bmi1, p16INK4A and p14ARF to the same regions by staining serially-
cut slides (Fig. 2). In each specimen, normal prostatic glands, high-
grade PINs, and carcinomas were located. In tissues derived from the
same patient, high levels of Bmi1 were associated with decreases in
p16INK4A in normal prostatic glands (Fig. 2), whereas low levels of
Bmi1 were associated with high levels of p16INK4a in PINs (Fig. 2). The
Bmi1-positive carcinomas also expressed reduced p16INK4A (Fig. 2). In
terms of p14ARF, while Bmi1 positivity did not associate with p14ARF
reduction in normal prostate glands, the presence of Bmi1 associatedwith decreases in p14ARF in PINs and carcinoma (Fig. 2, Table 3). By
comparing the mean percentages of cells stained in normal prostatic
glands, PINs, and carcinomas for each individual specimen using t-
tests, it was revealed that Bmi1-positive cells associated with
signiﬁcant p16INK4A reduction in normal (pb0.05) and PIN (pb0.05)
tissues (Table 3). This inverse correlation was also conﬁrmed by
Pearson correlation tests (data not shown). Among the epithelial cells
present in normal and PIN tissues, 25% and 75% of Bmi1-positive cells
are p16INK4A positive and negative, respectively, compared to 52.4%
and 47.6% of Bmi1-negative normal epithelial cells being p16INK4A
Table 3
Quantiﬁcation of immunohistochemistry staining on prostate tissues
Prostate tissue p16lnk4A+ p16lnk4A− p-value p14ARF+ p14ARF− p-value
Normal
Bmi1+ 25.6±5.3% 74.4±8.2% 0.049 55.5±6.7 44.5±8.3% 0.897
Bmi1− 52.4±7.4% 47.6±3.5% 51.2±5.6% 48.8±5.2%
PIN
Bmi1+ 24.6±8.5% 75.4±6.5% 0.012 35.8±5.1% 64.2±4.2% 0.034
Bmi1− 65.5±5.9% 34.5±7.8 59.8±3.4% 40.2±4.5%
Carcinoma
Bmi1+ 26.2±4.5% 73.8±6.9% 0.925 30.1±4.0% 69.9±8.0% 0.051
Bmi1− 25.8±8.0% 74.2±7.7% 44.6±3.2% 55.4±4.5%
Note: Two-tailed t-tests were used to compare the mean percentages of cells stained in
the individual tissues. Data presented are mean percentage of cells stained±SE.
Table 2
Bmi1 positive cells in primary prostate cancer
Normal 27.8±3.1%
PIN 30.9±5.2%
Carcinoma 39.1±3.2%
Note: Mann–Whitney p-values: 0.452 for Normal vs PIN, 0.014 for Normal vs carcinoma,
and 0.051 for PIN vs carcinoma. 1000 cells were counted for each tissue (normal, PIN,
and carcinoma) for all 51 primary prostate cancer specimens.
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negative PIN cells being p16INK4A positive and negative, respectively
(Table 3). This inverse expression pattern between Bmi1 and p16INK4A
suggests that Bmi1 inhibits p16INK4A in normal prostatic glands and
PINs. However, this inverse relationship was not observed in prostate
carcinoma (Table 3). An overall 74% of carcinoma cells expressed no
detectable p16INK4A in both Bmi1-positive and negative carcinoma
(Table 3). However, it is clear that loss of this inverse relationship in
carcinoma is not because of changes in the ratio between p16INK4A
positive and p16INK4A negative populations in Bmi1-positive carci-
noma, as this ratio remains comparable in normal prostatic glands,
PINs, and carcinomas (Table 3), but rather due to increases in p16INK4A
negative cells in Bmi1-negative carcinoma (Table 3). This would
strongly suggest that additional mechanisms have developed in
carcinoma to reduce p16INK4A expression. Consistent with this
inference, t-test analysis of p16INK4A positive and p16INK4A negative
populations in Bmi1-positive carcinoma revealed that the differenceFig. 3. Bmi1 inhibits the expression of p16INK4A and p14ARF and enhances hTERT
expression in prostate cancer cells. (A) DU145, PC3, and LNCaP cells were stably
transfected with empty retrovirus (pBabe) or Bmi1 retrovirus. Bmi1 expression was
examined by western blot using anti-FLAG and anti-Bmi1 (αBmi1) antibodies. The
expression of p16INK4A, p14ARF, and actin was also examined by western blot using
speciﬁc antibodies. (B) 293T cells were transiently transfected with empty vector or
Bmi1 (as indicated) with a hTERT promoter-driven luciferase construct plus a β-Gal
construct for 48 h. Luciferase and β-Gal enzymatic activities were determined.
Luciferase activities were normalized against β-Gal activities. Each transfection was
carried out in triplicate and the experiment was repeated twice.between these two populations is statistically signiﬁcant (pb0.009,
data not shown).
Analysis of Bmi1 and p14ARF expression in primary CaP tissues
demonstrated that Bmi1 did not inhibit p14ARF expression in normal
prostate epithelial cells (Table 3). However, Bmi1 suppresses p14ARF
expression in both PIN and carcinoma tissues, as an inverse relationship
between Bmi1-positive and p14ARF negative expression was observed
(Table 3). Taken together, we provide evidence indicating that Bmi1
plays a role in inhibiting p16INK4A expression in normal prostate
epithelial cells and PINs, and in inhibiting p14ARF expression in PIN and
carcinoma tissues (Table 3). The fact that Bmi1 only reduces p14ARF in
precancerous lesions (PINs) and carcinomas is consistent with the
established role of p14ARF in tumor surveillance during tumorigenesis,
as p14ARF will not be fully functional in normal cells [28]. Collectively,
these observations support the notion that Bmi1 promotes CaP
tumorigenesis by inhibiting p16INK4A and p14ARF expression.
3.4. Bmi1 sensitizes DU145 cells to form xenograft tumors in
immunocompromised mice
Although DU145 cells express mutant p16INK4A [27], the afore-
mentioned observations that Bmi1 suppresses p14ARF and enhances
hTERT expression in DU145 cells suggest that Bmi1 may promote
DU145 cells to form tumors in immunocompromised mice. To
examine this possibility, we have subcutaneously (s.c.) implanted
2×105 empty vector (EV) or Bmi1 stably expressing DU145 cells into
NOD/SCID mice (4 mice for each of EV and Bmi1-overexpressing cell
lines). In comparison to EV cells, Bmi1 DU145 cells formed larger
tumors (Table 4). When cultured as a monolayer, DU145 cell
proliferation was not enhanced by ectopic Bmi1 expression (data not
shown). Taken together, the above observations support the concept
that Bmi1 promotes prostate tumorigenesis via down-regulation of
tumor suppressors (p16INK4A and p14ARF) and up-regulation of hTERT.
4. Discussion
Bmi1 has recently been shown to immortalize mammary and
nasopharyngeal epithelial cells by upregulating hTERT and inhibiting
p16INK4A, thereby promoting the formation of epithelial malignancies
[20,17]. This is consistent with the observed increases in Bmi1 mRNA
in primary prostate cancer (an epithelial malignancy) [21]. However,Table 4
Bmi1 promotes DU145 cells to form xenograft tumors in NOD/SCID mice
Cell type No. of tumours per injection Mean volume (±SE)a
DU145 pBABE 8/8 204±45
DU145 Bmi1 8/8 517±81b
a Mean tumor volume (mm3) at 4 weeks post-injection.
b Signiﬁcantly greater volume according to a two-tailed independent t-test (pb0.05).
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fully investigated.
We show that elevated levels of Bmi1 protein are present in prostate
cancer. High levels of Bmi1 protein were detected in androgen-
independent PC3 and DU145 CaP cells compared to androgen-
dependent LNCaP cells (Fig. 1). In primary prostate carcinoma,
immunohistochemistry (Table 2) revealed increases in Bmi1 in carci-
noma cells when compared to normal prostatic epithelial cells. A similar
situation has also been reported for another PcG protein, CBX7 [26].
Bmi1 promotes CaP tumorigenesis by inhibiting the INK4A/ARF
locus. This locus on human chromosome 9p21 encodes p16INK4A and
p14ARF by alternative splicing and the use of different reading frames
[29]. Methylation of the p14ARF promoter has been detected in primary
CaP [30]. While loss of p16INK4A function has been observed in a
variety of cancers via homozygous deletion and promotermethylation
[31,32], the status of p16INK4A expression in CaP is complex. Mutation
of the p16INK4A gene in CaP is not a frequent event [33]. Methylation of
p16INK4A was associated with the reduction of p16INK4A mRNA and
protein in primary prostate cancer [27,34]. This event has been
reported to occur in 43% [27], 66% [35], and 80.9% [30] of primary CaP.
Paradoxically, overexpression of p16INK4A has also been observed in
43% [36], 65% [37], and 83% [38] of primary CaP. In all of these studies,
overexpression of p16INK4A was associated with adverse prognosis.
These discrepancies are most likely caused by the heterogeneous
nature of prostate cancer. By counting 1000 cells within normal
prostate glands, PINs, and carcinomas for all 51 primary CaP speci-
mens, we conclusively demonstrate that 74% of carcinomas expressed
undetectable p16INK4A protein (Table 3). While Bmi1 may play a major
role in inhibiting p16INK4A in normal prostate glands and PINs, Bmi1,
along with additional mechanisms, may also be in place to suppress
p16INK4A in carcinomas (Table 3), suggesting thatmaintaining p16INK4A
suppression is important for CaP formation. In our primary CaP
specimens, p16INK4A staining was detected exclusively in the nucleus,
suggesting p16INK4A as being functional. Our prostate carcinomaswere
within a narrow range of Gleason scores, with the majority having
scores of 6–7 (Table 1). 26% of our carcinomas expressed p16INK4A, an
observation consistent with a recent report showing 25% of low-grade
carcinomas being p16INK4A positive [39]. Additionally, Bmi1 also
inhibits p14ARF in PINs and carcinoma (Table 3). However, Bmi1 does
not play a role in inhibiting p14ARF expression in normal prostatic
epithelial cells (Table 3). This may be attributable to the fact that ARF
plays a major role in oncogene-provoked tumor surveillance [28]. The
lack of oncogenic signals, including the Bmi1 signal, in normal
prostatic epithelial cells may underlie the reason why Bmi1 does not
contribute to reducing p14ARF expression in these cells. Taken
together, our observations suggest that Bmi1 reduces INK4A/ARF
expression during the evolution of CaP formation from normal
epithelial cells to PIN and carcinoma.
Acknowledgements
We thank Drs. Xinchang Feng and Lieqi Liu for their excellent
technical support. C.F. is supported by studentship from FSORC, St.
Joseph's Hospital, Hamilton, Ontario, Canada. This work was
supported by grants from the Prostate Cancer Research Foundation
of Canada to DT (2005–2007, 2007–2008).References
[1] I.K. Park, D. Qian, M. Kiel, M.W. Becker, M. Pihalja, I.L. Weissman, S.J. Morrison, M.F.
Clarke, Bmi-1 is required for maintenance of adult self-renewing haematopoietic
stem cells, Nature 423 (2003) 302–305.
[2] A.V. Molofsky, R. Pardal, T. Iwashita, I.K. Park, M.F. Clarke, S.J. Morrison, Bmi-1
dependence distinguishes neural stem cell self-renewal from progenitor pro-
liferation, Nature 425 (2003) 962–967.
[3] S.W. Bruggeman, M.E. Valk-Lingbeek, P.P. van der Stoop, J.J. Jacobs, K. Kieboom, E.
Tanger, D. Hulsman, C. Leung, Y. Arsenijevic, S. Marino, M. van Lohuizen, Ink4a andArf differentially affect cell proliferation and neural stem cell self-renewal in
Bmi1-deﬁcient mice, Genes Dev. 19 (2005) 1438–1443.
[4] A.V. Molofsky, S. He, M. Bydon, S.J. Morrison, R. Pardal, Bmi-1 promotes neural
stem cell self-renewal and neural development but not mouse growth and
survival by repressing the p16Ink4a and p19Arf senescence pathways, Genes Dev.
19 (2005) 1432–1437.
[5] J. Chagraoui, S.L. Niessen, J. Lessard, S. Girard, P. Coulombe, M. Sauvageau, S.
Meloche, G. Sauvageau, E4F1: a novel candidate factor for mediating BMI1
function in primitive hematopoietic cells, Genes Dev. 20 (2006) 2110–2120.
[6] Y. Haupt, W.S. Alexander, G. Barri, S.P. Klinken, J.M. Adams, Novel zinc ﬁnger gene
implicated as myc collaborator by retrovirally accelerated lymphomagenesis in
E mu-myc transgenic mice, Cell 65 (1991) 753–763.
[7] M. van Lohuizen, S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden, A. Berns,
Identiﬁcation of cooperating oncogenes in E mu-myc transgenic mice by provirus
tagging, Cell 65 (1991) 737–752.
[8] Y. Haupt, M.L. Bath, A.W. Harris, J.M. Adams, bmi-1 transgene induces lymphomas
and collaborates with myc in tumorigenesis, Oncogene 8 (1993) 3161–3164.
[9] M.J. Alkema, H. Jacobs, M. van Lohuizen, A. Berns, Pertubation of B and T cell
development and predisposition to lymphomagenesis in Emu Bmi1 transgenic
mice require the Bmi1 RING ﬁnger, Oncogene 15 (1997) 899–910.
[10] S. Bea, F. Tort, M. Pinyol, X. Puig, L. Hernández, S. Hernández, P.L. Fernandez, M. van
Lohuizen, D. Colomer, E. Campo, BMI-1 gene ampliﬁcation and overexpression in
hematological malignancies occur mainly in mantle cell lymphomas, Cancer Res.
61 (2001) 2409–2412.
[11] J.C. van Galen, J.J. Muris, J.J. Oudejans, W. Vos, C.P. Giroth, G.J. Ossenkoppele, A.P.
Otte, F.M. Raaphorst, C.J. Meijer, Expression of the polycomb-group gene BMI1 is
related to an unfavourable prognosis in primary nodal DLBCL, J. Clin. Pathol. 60
(2007) 167–172.
[12] K. Mihara, M. Chowdhury, N. Nakaju, S. Hidani, A. Ihara, H. Hyodo, S. Yasunaga, Y.
Takihara, A. Kimura, Bmi-1 is useful as a novel molecular marker for predicting
progression of myelodysplastic syndrome and patient prognosis, Blood 107 (2006)
305–308.
[13] S. Vonlanthen, J. Heighway, H.J. Altermatt, M. Gugger, A. Kappeler, M.M. Borner, M.
van Lohuizen, D.C. Betticher, The bmi-1 oncoprotein is differentially expressed in
non-small cell lung cancer and correlates with INK4A-ARF locus expression, Br. J.
Cancer 84 (2001) 1372–1376.
[14] J.H. Kim, S.Y. Yoon, C.N. Kim, J.H. Joo, S.K. Moon, I.S. Choe, Y.K. Choe, J.W. Kim, The
Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates
with the reduced p16INK4a/p14ARF proteins, Cancer Lett. 203 (2004) 217–224.
[15] C. Leung, M. Lingbeek, O. Shakhova, J. Liu, E. Tanger, P. Saremaslani, M. Van
Lohuizen, S. Marino, Bmi1 is essential for cerebellar development and is
overexpressed in human medulloblastomas, Nature 428 (2004) 337–341.
[16] J.H. Kim, S.Y. Yoon, S.H. Jeong, S.Y. Kim, S.K. Moon, J.H. Joo, Y. Lee, I.S. Choe, J.W.
Kim, Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node
metastases in invasive ductal breast cancer, Breast 13 (2004) 383–388.
[17] L.B. Song, M.S. Zeng,W.T. Liao, L. Zhang, H.Y. Mo,W.L. Liu, J.Y. Shao, Q.L. Wu, M.Z. Li,
Y.F. Xia, L.W. Fu, W.L. Huang, G.P. Dimri, V. Band, Y.X. Zeng, Bmi-1 is a novel
molecular marker of nasopharyngeal carcinoma progression and immortalizes
primary human nasopharyngeal epithelial cells, Cancer Res. 66 (2006)
6225–6232.
[18] J.J. Jacobs, K. Kieboom, S. Marino, R.A. DePinho, M. van Lohuizen, The oncogene
and Polycomb-group gene bmi-1 regulates cell proliferation and senescence
through the ink4a locus, Nature 397 (1999) 164–168.
[19] K. Itahana, Y. Zou, Y. Itahana, J.L. Martinez, C. Beausejour, J.J. Jacobs, M. Van
Lohuizen, V. Band, J. Campisi, G.P. Dimri, Control of the replicative life span of
human ﬁbroblasts by p16 and the polycomb protein Bmi-1, Mol. Cell. Biol. 23
(2003) 389–401.
[20] G.P. Dimri, J.L. Martinez, J.J. Jacobs, P. Keblusek, K. Itahana, M. Van Lohuizen, J.
Campisi, D.E. Wazer, V. Band, The Bmi-1 oncogene induces telomerase activity and
immortalizes human mammary epithelial cells, Cancer Res. 62 (2002) 4736–4745.
[21] G.V. Glinsky, O. Berezovska, A.B. Glinskii, Microarray analysis identiﬁes a death-
from-cancer signature predicting therapy failure in patients withmultiple types of
cancer, J. Clin. Invest. 115 (2005) 1503–1521.
[22] O.P. Berezovska, A.B. Glinskii, Z. Yang, X.M. Li, R.M. Hoffman, G.V. Glinsky, Essential
role for activation of the Polycomb group (PcG) protein chromatin silencing
pathway in metastatic prostate cancer, Cell Cycle 5 (2006) 1886–1901.
[23] I. Horikawa, P.L. Cable, C. Afshari, J.C. Barrett, Cloning and characterization of the
promoter region of human telomerase reverse transcriptase gene, Cancer Res. 59
(1999) 826–830.
[24] D. Tang, H. Okada, J. Ruland, L. Liu, V. Stambolic, T.W. Mak, A.J. Ingram, Akt is
activated in response to an apoptotic signal, J. Biol. Chem. 276 (2001) 30461–30466.
[25] Y. Li, D.Wu, B. Chen, A. Ingram, L. He, L. Liu, D. Zhu, A. Kapoor, D. Tang, ATM activity
contributes to the tumor suppressing functions of p14ARF, Oncogene 23 (2004)
7355–7365.
[26] D. Bernard, J.F. Martinez-Leal, S. Rizzo, D. Martinez, D. Hudson, T. Visakorpi, G.
Peters, A. Carnero, D. Beach, J. Gil, CBX7 controls the growth of normal and tumor-
derived prostate cells by repressing the Ink4a/Arf locus, Oncogene 24 (2005)
5543–5551.
[27] S.G. Chi, R.W. deVere White, J.T. Muenzer, P.H. Gumerlock, Frequent alteration of
CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas,
Clin. Cancer Res. 3 (1997) 1889–1897.
[28] C.J. Sherr, Tumor surveillance via the ARF-p53 pathway, Genes Dev. 12 (1998)
2984–2991.
[29] D.E. Quelle, F. Zindy, R.A. Ashmun, C.J. Sherr, Alternative reading frames of the
INK4a tumor suppressor gene encode two unrelated proteins capable of inducing
cell cycle arrest, Cell 83 (1995) 993–1000.
648 C. Fan et al. / Biochimica et Biophysica Acta 1782 (2008) 642–648[30] M.O. Hoque, O. Topaloglu, S. Begum, R. Henrique, E. Rosenbaum,W. Van Criekinge,
W.H. Westra, D. Sidransky, Quantitative methylation-speciﬁc polymerase chain
reaction gene patterns in urine sediment distinguish prostate cancer patients
from control subjects, J. Clin. Oncol. 23 (2005) 6569–6579.
[31] P. Cairns, T.J. Polascik, Y. Eby, K. Tokino, J. Califano, A. Merlo, L. Mao, J. Herath, R.
Jenkins, W. Westra, et al., Frequency of homozygous deletion at p16/CDKN2 in
primary human tumours, Nat. Genet. 11 (1995) 210–212.
[32] J.G. Herman, A. Merlo, L. Mao, R.G. Lapidus, J.P. Issa, N.E. Davidson, D. Sidransky,
S.B. Baylin, Inactivation of the CDKN2/p16/MTS1 gene is frequently associated
with aberrant DNA methylation in all common human cancers, Cancer Res. 55
(1995) 4525–4530.
[33] D.I. Quinn, S.M. Henshall, R.L. Sutherland, Molecular markers of prostate cancer
outcome, Eur. J. Cancer. 41 (2005) 858–887.
[34] N. Konishi, M. Nakamura, M. Kishi, M. Nishimine, E. Ishida, K. Shimada,
Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within
prostate carcinomas, Am. J. Pathol. 160 (2002) 1207–1214.[35] N. Konishi, M. Nakamura, M. Kishi, M. Nishimine, E. Ishida, K. Shimada, DNA
hypermethylation status of multiple genes in prostate adenocarcinomas, Jpn. J.
Cancer Res. 93 (2002) 767–773.
[36] C.T. Lee, P. Capodieci, I. Osman, M. Fazzari, J. Ferrara, H.I. Scher, C. Cordon-Cardo,
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with
tumor recurrence in human prostate cancer, Clin. Cancer Res. 5 (1999) 977–983.
[37] S.M. Henshall, D.I. Quinn, C.S. Lee, D.R. Head, D. Golovsky, P.C. Brenner, W.
Delprado, P.D. Stricker, J.J. Grygiel, R.L. Sutherland, Overexpression of the cell cycle
inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early
relapse in prostate cancer patients, Clin. Cancer Res. 7 (2001) 544–550.
[38] D.F. Jarrard, J. Modder, P. Fadden, V. Fu, L. Sebree, D. Heisey, S.R. Schwarze, A. Friedl,
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and
metastatic human prostate cancer, Cancer Lett. 185 (2002) 191–199.
[39] Z. Zhang, D.G. Rosen, J.L. Yao, J. Huang, J. Liu, Expression of p14ARF, p15INK4b,
p16INK4a, and DCR2 increases during prostate cancer progression, Mod. Path. 19
(2006) 1339–1343.
